Limits...
A systematic review and meta-analysis of somatic and germline DNA sequence biomarkers of esophageal cancer survival, therapy response and stage.

Findlay JM, Middleton MR, Tomlinson I - Ann. Oncol. (2014)

Bottom Line: Meta-analyses were carried out for all reported markers associated with outcome measures by more than one study.Numerous DNA markers of outcome and stage have been reported, yet few are backed by high-quality evidence.Despite this, a small number of variants appear reliable.

View Article: PubMed Central - PubMed

Affiliation: Molecular and Population Genetics, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford Oxford OesophagoGastric Centre.

No MeSH data available.


Related in: MedlinePlus

PRISMA flow diagram.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4374384&req=5

MDU449F1: PRISMA flow diagram.

Mentions: Four thousand and four articles were identified, 762 retrieved for evaluation, 580 excluded (Figure 1) and 184 included (supplementary Tables S3–S25, available at Annals of Oncology online), published between 1989 and 2014. Seventy-three assessed markers of clinical outcome, 80 clinical outcome and stage and 29 stage alone. Survival measures were overall survival (OS; n = 133), disease-free survival (DFS; n = 20), recurrence (n = 19), progression-free survival (PFS; n = 4) and disease-specific survival (DSS; n = 4). Twenty nine studies assessed response to therapy (chemo ± radiotherapy, or biological). Eleven assessed treatment complications. Treatment intent was curative (n = 156), palliative (n = 5), mixed (n = 21) and unspecified in 1. Curative modalities were resection alone (n = 111), resection ± neoadjuvant (n = 33) or adjuvant (n = 2) therapy, or definitive chemoradiotherapy (n = 9). All chemotherapy regimens involved platinum agents with or without 5-fluorouracil, except three (bleomycin, gefitinib, irinotecan). One hundred and seventy-six studies were candidate based, and 6 genome-wide (1 SNP, 5 CNV). One hundred and seventeen studies assessed tumor variants, 64 germline and 1 both. Cell types assessed were SCC (n = 117), adenocarcinoma (AC) (n = 40), both (n = 3) and unspecified (n = 22).Figure 1.


A systematic review and meta-analysis of somatic and germline DNA sequence biomarkers of esophageal cancer survival, therapy response and stage.

Findlay JM, Middleton MR, Tomlinson I - Ann. Oncol. (2014)

PRISMA flow diagram.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4374384&req=5

MDU449F1: PRISMA flow diagram.
Mentions: Four thousand and four articles were identified, 762 retrieved for evaluation, 580 excluded (Figure 1) and 184 included (supplementary Tables S3–S25, available at Annals of Oncology online), published between 1989 and 2014. Seventy-three assessed markers of clinical outcome, 80 clinical outcome and stage and 29 stage alone. Survival measures were overall survival (OS; n = 133), disease-free survival (DFS; n = 20), recurrence (n = 19), progression-free survival (PFS; n = 4) and disease-specific survival (DSS; n = 4). Twenty nine studies assessed response to therapy (chemo ± radiotherapy, or biological). Eleven assessed treatment complications. Treatment intent was curative (n = 156), palliative (n = 5), mixed (n = 21) and unspecified in 1. Curative modalities were resection alone (n = 111), resection ± neoadjuvant (n = 33) or adjuvant (n = 2) therapy, or definitive chemoradiotherapy (n = 9). All chemotherapy regimens involved platinum agents with or without 5-fluorouracil, except three (bleomycin, gefitinib, irinotecan). One hundred and seventy-six studies were candidate based, and 6 genome-wide (1 SNP, 5 CNV). One hundred and seventeen studies assessed tumor variants, 64 germline and 1 both. Cell types assessed were SCC (n = 117), adenocarcinoma (AC) (n = 40), both (n = 3) and unspecified (n = 22).Figure 1.

Bottom Line: Meta-analyses were carried out for all reported markers associated with outcome measures by more than one study.Numerous DNA markers of outcome and stage have been reported, yet few are backed by high-quality evidence.Despite this, a small number of variants appear reliable.

View Article: PubMed Central - PubMed

Affiliation: Molecular and Population Genetics, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford Oxford OesophagoGastric Centre.

No MeSH data available.


Related in: MedlinePlus